A Post-marketing Surveillance to Assess Safety and Efficacy of Telostop Plus Tab.

IlDong Pharmaceutical

Status: Not yet enrolling

Conditions: Hypertension, Dyslipidemia

Study type: Observational

Funder types: Industry

Identifiers

NCT03648801

ID-TAR-P401

Details and patient eligibility

About

Post-marketing surveillance of Telostop Plus Tab.

Full description

This study will collect clinical data, mainly focused on safety, in Korean population as per the requirement of MFDS for market authorization.

Enrollment: 600 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• The patient who is first prescribed and administered Telostop plus Tab.

Exclusion criteria

• The patients who are overreacting to this drug or its components
• The patients with severe renal impairment

Trial design

600 participants in 1 patient group

Hypertention, Dyslipidemia

Description:

NA (Observation study)